Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation
The FDA’s decision is based on results from the Phase III ADVANCE-1 and ACCORD-2 studies.
Drug Development
LEO Pharma to acquire gene therapy company Replay
Ray Therapeutics receives EMA PRIME status for gene therapy
Regeneron Q1 2026 net income falls 10% to $727m
Arcera and Fosun sign MoU for neuroscience innovation
Rocket to sell PRV for $180m to advance gene therapy pipeline
BioMarin acquires Amicus Therapeutics for $4.8bn
FDA approves AstraZeneca’s Saphnelo for SLE
